Structure Therapeutics Inc. financial data

Symbol
GPCR on Nasdaq
Industry
Pharmaceutical Preparations
Location
611 Gateway Blvd Suite 223, South San Francisco, CA
State of incorporation
Cayman Islands
Fiscal year end
December 31
Former names
ShouTi Inc. (to 5/13/2022)
Latest financial report
10-K - Q4 2024 - Feb 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.77K % +69.3%
Debt-to-equity 4.12 % -42.3%
Return On Equity -15.8 % +51.8%
Return On Assets -15.1 % +50.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 172M shares
Common Stock, Shares, Outstanding 172M shares +23.4%
Entity Public Float 1.95B USD +289%
Common Stock, Value, Issued 17K USD +21.4%
Weighted Average Number of Shares Outstanding, Basic 158M shares +43.3%
Weighted Average Number of Shares Outstanding, Diluted 158M shares +43.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 109M USD +55.2%
General and Administrative Expense 49.4M USD +51.2%
Operating Income (Loss) -158M USD -54%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -122M USD -36.7%
Income Tax Expense (Benefit) 310K USD +31.4%
Net Income (Loss) Attributable to Parent -123M USD -36.7%
Earnings Per Share, Basic -0.78 USD/shares +3.7%
Earnings Per Share, Diluted -0.78 USD/shares +3.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 170M USD +30.6%
Cash, Cash Equivalents, and Short-term Investments 884M USD +89.1%
Assets, Current 891M USD +88.2%
Property, Plant and Equipment, Net 3.48M USD +7.75%
Operating Lease, Right-of-Use Asset 3.54M USD -31.2%
Other Assets, Noncurrent 5.11M USD +11247%
Assets 903M USD +87.4%
Accounts Payable, Current 8.02M USD +69.2%
Employee-related Liabilities, Current 7.29M USD +68.6%
Liabilities, Current 36M USD +45.6%
Operating Lease, Liability, Noncurrent 2.16M USD -46.1%
Other Liabilities, Noncurrent 302K USD +1.34%
Liabilities 38.5M USD +32.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 914K USD +75.4%
Retained Earnings (Accumulated Deficit) -329M USD -59.3%
Stockholders' Equity Attributable to Parent 865M USD +90.9%
Liabilities and Equity 903M USD +87.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -34.1M USD -67.8%
Net Cash Provided by (Used in) Financing Activities 702K USD -99.6%
Net Cash Provided by (Used in) Investing Activities 1.42M USD
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 172M shares +23.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -32M USD -132%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 170M USD +30.6%
Deferred Tax Assets, Valuation Allowance 68.2M USD +32.3%
Deferred Tax Assets, Gross 69.1M USD +30.9%
Operating Lease, Liability 3.86M USD -29.2%
Depreciation 222K USD +217%
Payments to Acquire Property, Plant, and Equipment 162K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -122M USD -37.2%
Lessee, Operating Lease, Liability, to be Paid 4.19M USD -31.8%
Property, Plant and Equipment, Gross 5.11M USD +32.1%
Operating Lease, Liability, Current 1.7M USD +17.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.88M USD -5.99%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.93M USD +6.94%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 327K USD -52.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 381K USD -80.5%
Deferred Tax Assets, Operating Loss Carryforwards 26.2M USD -10.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 100M shares 0%
Unrecognized Tax Benefits 7.95M USD +806%
Lessee, Operating Lease, Liability, to be Paid, Year Four 384K USD
Operating Lease, Payments 300K USD +200%
Additional Paid in Capital 1.19B USD +81%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 913K USD -25.4%
Share-based Payment Arrangement, Expense 18.8M USD +129%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%